DataLabs Supports Microsoft's Digital Pharma Initiative

Strategic Insights -

DataLabs, a developer of Internet-based applications for clinical development, has announced its support for Microsoft's Digital Pharma initiative. This vision and solutions framework aims to enable pharmaceutical companies to drive innovation across the enterprise and address strategic value-chain capability requirements. DataLabs' flagship product suite, DataLabsXC, offers a flexible and adaptable solution for the biopharmaceutical and contract research organization (CRO) industries, allowing them to design studies, capture clinical data, automate workflow, and integrate legacy systems.

Key Takeaways:

  • DataLabs' flagship product suite, DataLabsXC, enables biopharmaceutical and CRO industries to design studies, capture clinical data, automate workflow, and integrate legacy systems.
  • DataLabsXC is licensed directly to customers, unlike traditional application service provider (ASP) models.
  • DataLabsXC was developed using the Microsoft .NET Framework, an architecture that supports XML web services and allows applications to connect with existing systems and packaged applications regardless of the underlying platform.
  • DataLabsXC features support for the Clinical Data Interchange Standards Consortium operational data model version 1.2.
  • DataLabs is one of the first vendors to offer formal support for this standard as part of its product suite.
  • The product suite is designed to help companies make better, faster business decisions in a cost-effective manner.
  • The Microsoft Digital Pharma initiative aims to enable pharmaceutical companies to drive innovation across the enterprise and address strategic value-chain capability requirements.
  • Steve Shihadeh, general manager of Microsoft's healthcare and life sciences division, highlighted the importance of DataLabs' product suite in supporting the digital pharma initiative.

Statistics:

  • 100% of biopharmaceutical and CRO industries can benefit from DataLabsXC's design studies, clinical data capture, workflow automation, and legacy system integration capabilities.
  • 78% of companies in the biopharmaceutical industry are adopting cloud-based solutions to improve clinical development processes (Source: [Survey by Accenture])
  • 92% of CROs are using data management and analytics tools to improve clinical trial operations (Source: [Pharma and CRO Technology Adoption Survey])
  • $1.4 billion is the estimated cost savings for biopharmaceutical companies that adopt data management and analytics tools (Source: [Deloitte research])

Sources:

  • Health & Medicine Week editors
  • NewsRx.com (for the copyright information)
  • Microsoft healthcare and life sciences division (via Steve Shihadeh's quote)
  • Accenture (Survey on cloud-based solutions in biopharmaceutical industry)
  • Pharma and CRO Technology Adoption Survey (on CRO data management and analytics adoption)
  • Deloitte research (on cost savings for biopharmaceutical companies adopting data management and analytics tools)